Allergan plc announces it has received approval from the US Food and Drug Administration to market NATRELLE INSPIRA SoftTouch Breast Implants for women undergoing breast reconstruction, augmentation, or revision surgery.
With this recent granting, Allergan notes in a media release that the NATRELLE line now offers three levels of gel firmness for differing levels of form stability.
“Adding NATRELLE INSPIRA SoftTouch breast implants to our already robust line of offerings gives Allergan the most extensive variety of implants in the industry and provides doctors with a wide range of options,” says David Nicholson, Chief R&D Officer of Allergan plc, in the release. “Now, the INSPIRA line of breast implants helps physicians to better meet diverse, patient-specific needs based on available breast tissue and desired outcomes.”
For more information, visit Allergan plc.
[Source(s): Allergan plc, PR Newswire]